Krishna Yalla

Dr. Krishna Yalla serves as a Research Associate at the Translational Pharmacology Laboratory within the Wolfson Wohl Cancer Research Centre at the University of Glasgow, focusing on molecular mechanisms bridging cancer biology and neurobiology. His work integrates pharmacological approaches to study signaling pathways in disease contexts.

His research spans two primary domains: cancer biology (particularly Trib2-mediated acute myeloid leukemia mechanisms involving drug resistance, leukemia-initiating cells, and Bcl2 regulation) and neurobiology (centering on DISC1 protein stability via ubiquitin-proteasome system and SUMOylation in neural development). This dual focus reveals connections between oncogenic pathways and neurodevelopmental disorders, with translational implications for targeted therapies in both fields.

Analysis of his 2010-2022 publications shows an evolution from cardiovascular/cAMP signaling research toward specialized cancer and neurodevelopmental studies. Recent work emphasizes Trib2 in leukemia pathogenesis and DISC1-related neural mechanisms, highlighting protein degradation systems, cell cycle regulation, and stress response pathways. Key trends include molecular pharmacology applications for drug repurposing (e.g., moexipril as PDE4 inhibitor) and clinical translation (CDC7 inhibitor trials).

Based at the Wolfson Wohl Cancer Research Centre's Translational Pharmacology Laboratory, Dr. Yalla collaborates with Dr. Karen Keeshan's group on leukemia projects and neurobiology teams on DISC1 studies. The lab employs molecular, cellular, and computational techniques to investigate signaling pathways, with infrastructure supporting translational cancer research from basic science to clinical applications.